Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance

27 Jun 2019

Abstract excerpt

RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1 P29S in melanoma development and reveal that RAC1 P29S activates PAK, AKT, and a gene expression program initiated by the SRF/MRTF transcriptional pathway, which results in a melanocytic to mesenchymal phenotypic switch. Mice with ubiquitous expression of RAC1 P29S from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31257073
DOI: 10.1016/j.ccell.2019.05.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistancePMID 31257073Read ↗

RAC1 and melanoma.Semantic proximity Read ↗

RAC1 P29S regulates PD-L1 expression in melanoma.Semantic proximity Read ↗

RACK1 cooperates with NRASQ61K to promote melanoma in vivo.Semantic proximity Read ↗

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.Semantic proximity Read ↗

Targeting effector pathways in RAC1P29S-driven malignant melanoma.Semantic proximity Read ↗

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.Semantic proximity Read ↗

Characterisation and outcome of RAC1 mutated melanoma.Semantic proximity Read ↗

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.Semantic proximity Read ↗

RAS pathway regulation in melanoma.Semantic proximity Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

Emerging role of ARHGAP29 in melanoma cell phenotype switching.Semantic proximity Read ↗

Rac and Rho driving tumor invasion: who's at the wheel?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.